	US 12,497,612 B2
	Gene replacement therapy for FOXG1 syndrome
Dan Wang, Worcester, MA (US); Guangping Gao, Worcester, MA (US); and Ailing Du, Worcester, MA (US)
Assigned to University of Massachusetts, Westborough, MA (US)
Appl. No. 17/910,574
Filed by University of Massachusetts, Westborough, MA (US)
PCT Filed Mar. 8, 2021, PCT No. PCT/US2021/021358 § 371(c)(1), (2) Date Sep. 9, 2022, PCT Pub. No. WO2021/183433, PCT Pub. Date Sep. 16, 2021.
Claims priority of provisional application 62/987,307, filed on Mar. 9, 2020.
Prior Publication US 2023/0151359 A1, May 18, 2023
Int. Cl. C12N 15/11 (2006.01); A61P 43/00 (2006.01); C12N 15/86 (2006.01)

CPC C12N 15/11 (2013.01) [A61P 43/00 (2018.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/30 (2013.01)]

15 Claims

1. A recombinant adeno-associated virus (rAAV) comprising an isolated nucleic acid, and at least one AAV capsid protein;

wherein the isolated nucleic acid comprises the nucleic acid sequence set forth in any one of SEQ ID NOs: 3 and 8-13.